A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance
of epidermal-barrier function that results in intensely pruritic subacute and chronic
eczematous plaques. The current therapy of AD is reactive, where the flares are treated
through symptomatic management with topical corticosteroids and calcineurin inhibitors. Given
that these medications have long-term side-effects, and given the chronically relapsing
immunopathogenic nature of AD, there is an imperative need for safer anti-inflammatory
medications. Haus Bioceuticals (Haus) has developed a novel topical treatment for
eczema/atopic dermatitis (AD) denoted HAT01H, and have demonstrated that HAT01H is safe and
profoundly effective in the treatment of AD, controlling signs and symptoms in 85% of
patients with AD. This study is aimed to further test the efficacy and safety of topical
HAT01H in patients with moderate to severe atopic dermatitis.